OPEN END TURBO OPTIONSSCHEIN - MODERNA | Real-time Bid/Ask 08:23:36 2024-06-20 am EDT | ||
| 6.82 EUR / 6.91 EUR | +4.17% |
|
| Current month | -13.18% | ||
| 1 month | -1.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 6.82 | +3.49% |
| 24-06-19 | 6.59 | -3.51% |
| 24-06-18 | 6.83 | -5.66% |
| 24-06-17 | 7.24 | -2.43% |
| 24-06-14 | 7.42 | -5.60% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 08:05 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | J.P. Morgan |
| WKN | JA5Z85 |
| ISIN | DE000JA5Z857 |
| Date issued | 2022-05-06 |
| Strike | 61.09 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.96 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.19 € |
|---|---|
| Lowest since issue | 0.66 € |
| Spread | 0.09 € |
| Spread % | 1.30% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Certificates
- Certificat
